Brief: Evelo Biosciences, Abdul Latif Jameel Health Announce Strategic Collaboration

Evelo Biosciences

23/03/2021 08:16

March 23 (Reuters) - EVELO BIOSCIENCES INC  EVLO.O :
    * EVELO BIOSCIENCES & ABDUL LATIF JAMEEL HEALTH ANNOUNCE
STRATEGIC
COLLABORATION 
    * COLLABORATION TO DEVELOP AND COMMERCIALIZE EVELO’S LEAD
INFLAMMATION PRODUCT CANDIDATE EDP1815 IN THE MIDDLE EAST,
TURKEY, AND AFRICA
    * THE COMPANY IS ALSO CONDUCTING A PHASE 2 CLINICAL TRIAL
FOR
EDP1815 IN PSORIASIS, AS WELL AS TWO TRIALS IN PATIENTS
HOSPITALIZED WITH COVID-19
    * TOGETHER, EVELO AND ABDUL LATIF JAMEEL HEALTH WILL WORK TO
ADDRESS THE SIGNIFICANT DISPARITY IN ACCESS TO MEDICAL CARE IN
THE FASTEST-GROWING POPULATIONS AND GROWTH ECONOMIES OF THE
DEVELOPING WORLD
    * UNDER THE TERMS OF THE AGREEMENT, EVELO RECEIVED AN
UPFRONT
PAYMENT AND EQUITY INVESTMENT
    * EVELO WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND
MANUFACTURING
OF EDP1815, WHILST ABDUL LATIF JAMEEL HEALTH WILL BE RESPONSIBLE
FOR REGULATORY SUBMISSIONS AND COMMERCIALIZATION ACTIVITIES IN
THE AGREED-UPON REGIONS
    * EVELO AND ABDUL LATIF JAMEEL HEALTH WILL PARTICIPATE IN A
50:50 

Further company coverage:  EVLO.O 

 ((Reuters.Briefs@thomsonreuters.com;))